Colorectal cancers (CRCs) express the WNT effector protein β-catenin in a heterogeneous subcellular pattern rather than uniformly in the nucleus. In this study, we investigated this important aspect of molecular heterogeneity in CRCs by analyzing its basis and relationship with tumor initiating capability. CRC cells expressing the highest WNT expression showed only a marginal increase in tumor initiation capacity. Notably, high WNT activity correlated with a coincident activation of robust MAPK signaling, which when upregulated by KRAS expression or downregulated by EGFR inhibition elicited parallel effects on WNT activity.
INTRODUCTION
Colorectal cancer (CRC) derives from normal colonic mucosa by stepwise accumulation of somatic genetic alterations, starting with inactivation of the tumor suppressor gene Adenomatous Polyposis Coli (APC) or activation of the oncogene ß-catenin (CTNNB1) (1) .
Among additional mutations identified frequently in human CRC are those in the KRAS oncogene, which occur in over 40% of cases (2) and activate signaling through the Mitogen Activated Protein Kinase (MAPK) pathway. APC is a negative regulator of WNT signaling and its mutational inactivation leads to accumulation of β-catenin, which associates with transcription factors of the T-cell Factor (TCF) family to activate WNT target genes (3) .
Although this understanding implies that the WNT pathway is uniformly active in all tumor cells that carry mutant APC or CTNNB1, colon cancers show substantial heterogeneity in the accumulation of nuclear β-catenin, which is evident in about 60% of resected tumor specimens, often at the invasive front (4, 5) . Such differential accumulation suggests that, in addition to APC and CTNNB1 mutations, other pathway alterations or stimulatory factors external to tumor cells influence β-catenin distribution and WNT pathway activity in CRC (6, 7) . For example, CpG island hypermethylation (CIMP) is inversely associated with CTNNB1 activation (8) and APC mutation (9) , and amplification of the CDK8 locus, which encodes a member of the mediator complex, contributes to CTNNB1-driven cell transformation (10) .
Like other solid tumors, CRCs contain a subpopulation of cells that differ from the majority of tumor cells in displaying an enhanced potential to establish tumors in immune compromised mice; these are thought to represent the clonogenic tumor-initiating cells (11) (12) (13) . Because some surface markers that have been used to enrich tumor-initiating cells, including CD133 and CD44, are proposed targets of WNT signaling (14, 15) , one possibility is that cells showing nuclear β-catenin may harbor the highest tumorigenic potential. In support of this idea, a recent report showed that cell populations isolated from CRCs on the basis of high activity of a lentiviral WNT pathway reporter were more tumorigenic than cells with low or absent reporter activity (16) . By contrast, we report here that our independent investigation of differential WNT activity in CRC cell lines and primary CRC xenografts revealed poor correlation between increased WNT activity and the potential to initiate tumors. In examining correlates of WNT signaling heterogeneity, we further found that nuclear β-catenin accumulated most in cells with active MAPK signaling and that nuclear β- Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 8, 2012 ; DOI: 10.1158/0008-5472. catenin correlated with KRAS mutation in a large collection of surgical CRC cases. Moreover, gain-and loss-of-function studies revealed regulation of differential WNT activity by MAPK signaling. Thus, common mutations that activate MAPK signaling through the KRAS oncogene may be especially important in CRC in part by virtue of their effects on WNT pathway activity. One important feature of our study is the use of both cell lines and primary human CRCs, which may model tumor properties more accurately than do CRC cell lines alone. 
MATERIALS AND METHODS

Cloning of lentiviral vectors
All template plasmids were obtained through Addgene (www.addgene.org). TOP-GFP was constructed by replacing the PGK promoter in the lentiviral vector pRRLSIN.cPPT.PGK-GFP. WPRE (Constructed in Didier Trono's lab) with a 7xTCF/LEF optimal promoter cassette (7xTOP) from the M50 Super TOPFlash plasmid (17) . To construct the double color vector TOP-GFP.mC, we inserted 4 additional TCF/LEF binding sites (GATCAAAGG) into a lentiviral TOP-dGFP reporter containing 3 such binding sites (18) , yielding 7xTOP-dGFP. We then amplified this cassette using PCR and inserted it into the Hpa1 site of lentiviral PGKH2BmCherry (19) . To convert destabilized dGFP into enhanced eGFP, we used site directed mutagenesis (Stratagene) to insert a stop codon between GFP and the attached ornithine decarboxylase sequence, yielding lentiviral TOP-GFP.mC. To construct the control vectors FOP-GFP and FOP-GFP.mC, we replaced 7xTOP cassettes with synthetic 7xFOP cassettes (IDT-DNA), which carry mutated TCF/LEF binding sites (GgcCAAAGG 
Tumor induction and treatment in mice
Mice were housed in micro-isolator cages in a pathogen-free colony; housing and or PBS (control) was injected into the peritonea of tumor-bearing mice every other day, starting after subcutaneous tumors exceeded >0.5 cm; CTNNB1 staining was analyzed after 10 days of cetuximab treatment.
Gene expression analyses
RNA was isolated from flow-sorted GFP high and GFP low tumor cells using TRIzol Reagent (Invitrogen), treated with DNase, and first strand cDNA was synthesized using a QuantiTect
Reverse Transcription Kit (Qiagen). Quantitative real-time PCR applied 40 cycles of amplification at 95°C (15 sec) and 60°C (1 min) using Sybr green (Roche), a 7500 instrument (Applied Biosystems, Foster City, CA), and the primers listed in Suppl. Table 1 . Real-time RT-PCR results were first normalized to Gapdh mRNA levels in the same sample and then to levels of the corresponding transcript in GFP low tumor cells. For transcriptional profiling, total RNA was converted to cDNA, linearly amplified using the NuGEN Ovation V2 Amplification System (NuGEN, San Carlos, CA), and hybridized to Human Genome U133A 2.0 arrays (Affymetrix, Santa Clara, CA) according to the manufacturer's protocols. Expression microarray data were analyzed using the dChip package (22) , considering transcripts that achieved a minimum change of 1.2-fold between two groups as differentially expressed.
Histology and immunohistochemistry
Tumor tissues were fixed in 4% paraformaldehyde, dehydrated in ethanol and xylenes, and system. Slides were then washed in PBS and stained with β-catenin Ab as described above.
CRC specimen collections and mutational analysis
A total of 301 paraffin-embedded CRC tissues were analyzed. KRAS mutations were determined on DNA extracted from the xenograft tumors and archived tissues by targeted pyrosequencing for codons 12 and 13 (23) . Xenograft tumors were additionally tested for mutations in NRAS codons 12, 13 and 61, and BRAF codon 600 (24) . Frequency data were analyzed using the Chi-squared-test. Statistical procedures applied SPSS version 19.0 (SPSS Inc.). Human subjects committees at the respective hospitals approved the study. 
RESULTS
Isolation of CRC cell populations with differing levels of WNT pathway activity
Caco2 and SW1222 human CRC cells carry classical APC mutations (25) and form welldifferentiated glandular tumors in NOD/SCID mice, with heterogeneous intratumoral expression and distribution of β-catenin (Suppl. Fig. 1A-B Fig. 1A ). To test reporter specificity, we used FOP-GFP, a control vector with mutant TCF-binding sites (Suppl. Figure 2A ). Cells were expanded clonally to exclude the nontransduced population and then xenografted into NOD/SCID mice (Fig. 1B) . These clones showed high GFP in all cultured cells (Suppl. Fig 2B) , whereas their xenografts showed differential GFP expression ( Figure 1C , Suppl. Figure 2C ), pointing to an environmental influence on WNT heterogeneity. In tumors expanded from Caco2 TOP-GFP cells, the GFP signal co-localized with nuclear staining for β-catenin (Fig. 1C ) and in SW1222 TOP-GFP tumors, GFP and nuclear β-catenin largely overlapped (Suppl. Figure 2C ). Moreover, GFP expression marked tumor cells with active, dephospho-β-Catenin (Suppl. Figure 2D ).
To mark tumor cells with differential WNT activity in primary CRCs, we first propagated fresh tumors as xenografts in mice, noting that they preserved their original morphology and displayed differential expression of nuclear β-catenin (Suppl. Fig. 1B-C) . Because primary tumors have a heterogeneous composition, we preferred to avoid in vitro expansion of single transduced cells, which might select atypical clones. Instead we constructed a twocolor reporter, TOP-GFP.mC, which allows constitutive nuclear mCherry expression in infected cells and regulated GFP expression in response to WNT pathway activity (Fig. 1D , Suppl. Fig. 2E ). Fluorescence microscopy revealed nuclear mCherry expression in transduced primary CRC cells and a subset of these cells expressed GFP (Fig. 1E) . Thus, after excluding non-transduced, mCherry-negative tumor cells, GFP again marked rare tumor cells that showed nuclear β-catenin (Fig. 1F) .
We isolated GFP high and GFP low cell fractions by flow cytometric sorting of disaggregated xenografts from TOP-GFP transduced cell lines and TOP-GFP.mC transduced primary CRCs. 
The GFP high population showed significantly higher mRNA levels of known WNT target genes, including the intestinal stem cell marker LGR5 (Fig. 1G-H , Suppl. Figure 3A) . Gene expression profiles of GFP high and GFP low cells from Caco2 TOP-GFP revealed differential expression of 692 transcripts. Of these, 11 are annotated components of the WNT pathway and 9 of the 11 transcripts showed higher expression in the GFP high cell fraction (Suppl. Fig. 3B ). Thus, TOP-GFP based constructs reliably marked a WNT-active subpopulation of CRC cells with nuclear β-catenin and allowed their isolation from bulk xenografts. However, the lesser enrichment for nuclear β-catenin and lower differential expression of WNT target genes among GFP high cells from SW1222 TOP-GFP suggest that CRCs vary in the degree of heterogeneity in WNT activity.
Tumor cell fractions with different levels of WNT activity are equally tumorigenic
To characterize tumor cells with high and low WNT activity, we examined differential expression of all cell surface marker genes, as defined by Gene Ontology criteria, in GFP high and GFP low cells isolated from Caco2 TOP-GFP xenografts. Among the 16 differentially expressed surface markers were several that are reported or suspected to mark tumorigenic CRC cells, including CD133 (PROM1), CD166 (ALCAM), and LGR5; expression of these transcripts was consistently higher in the GFP high than in the GFP low cell fraction ( Fig. 2A) . mRNA expression profiles of TOP-GFP.mC-transduced GFP high and GFP low primary tumor cells also showed increased levels of these candidate stem and progenitor cell markers ( Fig. 2A) . These results suggested the possibility that CRC cells with the highest WNT activity might harbor increased tumorigenic potential, as others report (16) . To test this hypothesis, we injected limiting dilutions of GFP high and GFP low colon cancer cells into both flanks of NOD/SCID mice and followed the appearance of tumors. Indeed, GFP high cells from Caco2 TOP-GFP xenografts were more tumorigenic than the GFP low cell fraction and the tumors grew faster (Fig. 2B , Suppl. 
High WNT activity is associated with MAPK pathway activation in colon cancer cells
Recent data from zebrafish embryos suggest a role for Mitogen Activated Protein Kinase (MAPK) signaling in nuclear accumulation of β-catenin in the presence of mutant APC (26) .
To investigate if MAPK activity has a role in differential WNT activity in CRC cell subpopulations, we first compared the profile of transcripts that are altered in GFP high or GFP low tumor cells to a canonical MAPK target gene signature (27) . Of the 31 differentially expressed genes common to the two sets (Fig. 3A) , 29 were expressed at higher levels in WNT-active, GFP high cells compared to GFP low cells (p < 10 We then tested our xenograft sources for mutations most likely to affect MAPK signaling, in KRAS, BRAF and NRAS. Both cell lines were wild type for all 3 genes but primary Tu1 carried the V600E mutation in BRAF and primary Tu3 had a G12A mutation in KRAS. Surprisingly, although MAPK activation is considered a global feature of CRCs carrying such mutations, the activity marker phospho-ERK appeared only in a fraction of the cells in every tumor source ( Fig. 3C and data not shown). Importantly, immunostaining of Caco2 and primary colon cancer xenografts revealed co-localization of p-ERK and nuclear β-catenin (Fig. 3C) .
Thus, MAPK signaling is heterogeneous in CRC and increased in the tumor cell fraction with high WNT activity and nuclear accumulation of β-catenin.
To assess this association in clinical samples, we examined MAPK signaling and nuclear β-catenin accumulation in 301 primary CRCs with known KRAS mutation status. Similar to the xenografts, phospho-ERK immunostaining in 118 of these CRC specimens confirmed nonuniform MAPK signaling, irrespective of the underlying KRAS gene status (Suppl. Figure 5A ).
We then scored nuclear β-catenin in tissue sections on a scale from 0 (no nuclear β-catenin) to 3 (most tumor cells showing strong nuclear β-catenin), hence classifying cases as β-catenin low (scale 0-1) or β-catenin high (scale 2-3, Fig. 3D ), and observed that KRAS mutant tumors are significantly enriched for high nuclear β-catenin (Fig. 3E-F) . Taken together, these data support the idea that active KRAS might contribute to nuclear accumulation of β-catenin in CRC, where both MAPK signaling and WNT activity show intra-tumor heterogeneity. These findings suggested roles for KRAS and MAPK signaling in differential WNT activity. 
Functional relationship of MAPK and WNT pathway activities
To test if MAPK pathway activation influences WNT pathway activity, we constructed a lentiviral vector to express constitutively active KRAS and, as a marker of cell infection, GFP (Fig. 4A) . Increased phospho-ERK levels in transduced cells verified that introduction of this vector activates MAPK signaling, as expected (Fig. 4A) . We infected CRC cell lines and primary tumors with low-titer lentivirus and grafted the cells in NOD/SCID mice to obtain tumors containing a mix of infected and uninfected tumor cells (Fig. 4A) . Immunostaining of tumor sections revealed increased β-catenin levels and its nuclear localization in transduced, GFP + tumor cells (Fig. 4B, Suppl. Fig. 5B ). The levels of WNT target transcripts were also increased selectively in the transduced cell fractions (Suppl. Fig. 5C ). Thus, forced activation of MAPK signaling through high levels of constitutively active KRAS leads to nuclear accumulation of β-catenin and increased WNT activity in CRC.
To test if inhibition of MAPK signaling opposes β-catenin accumulation, we treated cultured CRC cells and mice bearing primary CRC xenografts with the epidermal growth factor receptor (EGFR) antibody cetuximab, which inhibits cellular MAPK activity (28) .
Treated tumors showed significantly fewer cells with nuclear β-catenin (Fig. 4C-D) . Likewise, treatment of cultured Caco2 TOP-GFP cells reduced expression of GFP and WNT target genes (Suppl. Fig. 5D ). Moreover, primary tumor xenografts carrying the WNT reporter TOP-GFP.mC showed reduced GFP fluorescence and depletion of the GFP high cell fraction (Fig. 4E-F ). Thus, EGFR antibody-mediated blockade of MAPK signaling reduces WNT pathway activity in CRC cells. Surprisingly, these effects were evident despite the presence of a KRAS mutation in one primary tumor. (29, 30) . Heterogeneity in nuclear β-catenin levels in most CRCs and differential expression of WNT target genes therefore present a paradox and suggest that additional factors contribute to WNT pathway activity (6, 7) . To isolate viable tumor cells showing differential WNT activity, we transduced xenografts of primary tumors and CRC cell lines with fluorescent reporters of canonical WNT activity (18) . Although cultured CRC cells expressed GFP uniformly, all xenografts displayed highly heterogeneous GFP expression, similar to a recent study (16) . Thus, the local environment or the 3-dimensional structure in xenografts seem necessary to reveal this latent heterogeneity. In tumor xenografts, nuclear β-catenin co-localized with high GFP expression as well as with enriched expression of WNT pathway components and WNT target genes in GFP high tumor cells. These data confirmed differential WNT pathway activity within CRCs and provided a reliable means to isolate cells with different levels of WNT activity. However, even though differentially expressed genes included the candidate human CRC stem-cell markers CD133, CD44, and CD166 (11) (12) (13) , and the intestinal stem cell marker LGR5 (31), WNT/GFP high cells from only 1 of the 5 tested sources showed a modest increase in tumor-initiating capacity.
These data from a small number of primary CRC specimens indicate that high WNT activity does not signify particular tumorigenic potential in CRC and is not a reliable marker for tumor initiation in xenografts. Accordingly, they question the generality of a recent argument that high WNT activity is a distinguishing feature of CRC stem cells (16) . The contrast between our findings and those of Vermeulen (16) tumor cell stimulation by the microenvironment may modulate β-catenin accumulation and WNT pathway activity (6, 16) , and studies in zebrafish embryos and a single CRC cell line recently implicated tumor cell MAPK signaling in the underlying mechanism (26) . Reinforcing this idea, we observed co-localization of nuclear β-catenin and the MAPK pathway indicator phospho-ERK in cell line and primary tumor xenografts, and expression of MAPK target genes is enriched in highly WNT-active CRC cells. We also detected a statistical association between nuclear β-catenin and the presence of activating mutations in the MAPK pathway gene KRAS. Our data are consistent with the observation that intestinal tumors in Kras G12V ; 
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